Recombinant Human Biosimilars (RUO)
Leinco Technologies is a leader in developing and manufacturing recombinant antibodies for early discovery research and diagnostics. Leinco’s extensive line of recombinant biosimilars follow stringent product specifications and undergo IMPACT testing.
Therapeutic antibodies are widely used for the treatment of diseases, including cancer and autoimmunity. However, therapeutic-grade biologics are expensive, challenging to source, and only available in large quantities, making studies using these antibodies cost prohibited. Research-grade biosimilar antibodies are produced by recombinant technology using the variable region sequences of therapeutic antibodies, resulting in the same specificities as approved biologics. Leinco’s recombinant biosimilar antibodies are ideal research tools as they are fast, inexpensive, manufactured in an animal free facility and formulated in sterile PBS buffer, free of additives or preservatives.
Leinco Technologies offers high-purity research-grade biosimilar antibodies with the same specifications as the following therapeutic antibodies: Trastuzumab, Efalizumab, Mogamulizumab, Rituximab, Tabalumab, Nivolumab, Natalizumab, Alemtuzumab, Ipilimumab, Drozitumab, Cetuximab, Briakinumab, Basiliximab, Sarilumab, Oxelumab, Adalimumab, and Bevacizumab. All antibodies are available with Fc Active or Fc Muted™ effector functions.
Research Use Only Biosimilar Offerings
*These products are for research use only and should not be used for any therapeutic purposes.